leadf
logo-loader
viewOrthocell Ltd

Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after announcing positive long-term clinical data for its CelGro® nerve repair study. The regenerative medicine company has decided that the clinical results have met the study objectives and has now closed recruitment. They're progressing regulatory applications in Australia and will start the US regulatory study shortly.

Quick facts: Orthocell Ltd

Price: 0.535 AUD

ASX:OCC
Market: ASX
Market Cap: $99.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Elementos Ltd's Chris Dunks 'upbeat' and says Oropesa drilling is going very...

Elementos Limited’s (ASX:ELT) (OTCMKTS:ELTLF) (FRA:9EM) Chris Dunks says the drilling campaign aimed at converting existing inferred resources into indicated resources at its flagship Oropesa Tin Project in Spain has confirmed significant zones of mineralisation. Assays for three diamond drill...

4 hours, 35 minutes ago

2 min read